OncLive Insights

Benjamin P. Levy, MD, and Misty D. Shields, MD, PhD, discuss Bridging the Gaps in lung cancer, a collection and review of updated data from the Winter Lung Cancer Conference 2025, that was significant to their practice and future implications of data across 6 key areas, including small cell lung cancer, perioperative treatment strategies in non–small cell lung cancer (NSCLC), advancements in unresectable early-stage NSCLC, treatment strategies for EGFR-mutated NSCLC, targeting ALK/ROS1/HER2/NRG1 mutations in NSCLC, and immunotherapy in advanced NSCLC.

Heather Wakelee, MD, FASCO, and Roy S. Herbst, MD, PhD, discuss how recent clinical trials demonstrate superior outcomes with combination therapies over single-agent osimertinib in EGFR-positive NSCLC, while highlighting the need for careful toxicity management and continued research to address treatment resistance.

Expert discussions on the latest advances in biomarker testing, endocrine resistance, and treatment sequencing with oral SERDs and other emerging therapies to enhance outcomes in HR+/HER2- metastatic breast cancer.

Sandra D’Angelo, MD, and Nam Bui, MD, examine synovial sarcoma's distinct molecular signature driven by the SS18-SSX fusion gene, highlighting critical unmet treatment needs that led to the groundbreaking approval of afami-cel, a MAGE-A4-targeted TCR therapy demonstrating promising efficacy in the SPEARHEAD-1 trial, potentially paving the way for broader adoption of TCR-based therapies in solid tumors.

Panelists discuss how genetic testing and RET-targeted therapies play a crucial role in guiding the treatment of advanced NSCLC, with a focus on optimizing first-line therapy and managing challenges in molecular testing and treatment sequencing.

Jorge Cortes, MD, and Stephen A. Strickland Jr, MD, MSCI,discuss how in the management of chronic myeloid leukemia (CML), clinicians must carefully monitor early treatment response milestones with first-line tyrosine kinase inhibitor therapy, consider appropriate switching strategies including BCR::ABL1 mutation testing, and select between newer agents such as asciminib and ponatinib based on patient-specific factors, trial data, and distinct safety profiles, particularly regarding cardiovascular toxicities.

Panelists discuss how recent advancements in ovarian cancer treatment, including biomarker-guided therapy, PARP inhibitors, combination therapies, and antibody-drug conjugates, are shaping personalized management strategies to improve patient outcomes.

Panelists discuss how emerging treatment strategies, including the use of CDK4/6 inhibitors and personalized risk stratification, are transforming the management of high-risk HR+/HER2– early-stage breast cancer, emphasizing the importance of multidisciplinary care and patient-specific approaches.

Panelists discuss optimizing treatment strategies for higher-risk myelofibrosis patients. They focus on managing thrombocytopenia, anemia, and ruxolitinib failure while exploring the role of JAK inhibitors and sequencing therapies.

Panelists discuss how the management of lung large cell neuroendocrine carcinoma (LCNEC) involves a multidisciplinary approach, focusing on molecular characterization, biomarker testing, and emerging treatment options, including novel targeted therapies and ongoing clinical trials.

Panelists discuss how current third-line treatment options for metastatic colorectal cancer, including regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, are selected based on patient-specific factors, safety profiles, and treatment goals, while also exploring future directions and unmet needs in mCRC management.

Elizabeth O’Donnell, MD, discusses how recent clinical trial findings are reshaping frontline treatment strategies for transplant-ineligible patients with newly diagnosed multiple myeloma, emphasizing the importance of patient-specific factors in therapy selection.

Furthermore, Douglas Sborov, MD, discusses how recent advancements in clinical trials and treatment strategies are reshaping the management of newly diagnosed multiple myeloma patients who are eligible for transplant.

Thomas Powles, MBBS, MRCP, MD, discusses currently available treatment options for previously untreated locally advanced and metastatic urothelial cancer. He presents a hypothetical clinical scenario and discusses his treatment approach to illustrate how he incorporates recent data into his clinical practice.

Margaret Kasner, MD, and Christian Fidler, MD, discuss how effective management of secondary acute myeloid leukemia (AML) in community settings requires early diagnosis, accurate risk stratification, timely referrals, personalized treatment approaches, robust supportive care, and close collaboration with academic centers to ensure optimal patient outcomes.

Panelists discuss how targeted therapies and effective management of adverse events, particularly in relation to the PI3K/AKT/PTEN pathway, are crucial for optimizing treatment outcomes in hormone receptor (HR)–positive, HER2-negative advanced breast cancer.

Nitin Jain, MD, and Joanna M. Rhodes, MD, MDCS, discuss how various aspects of chronic lymphocytic leukemia (CLL) management are approached, including treatment selection based on prior therapies and patient factors, the use of novel agents such as pirtobrutinib, strategies for relapsed/refractory (R/R) disease, treatment sequencing, and the role of multidisciplinary teams in optimizing patient care and outcomes.

Panelists discuss how recent advances in treating Lower-Risk Myelodysplastic Syndromes have impacted clinical practice, using hypothetical scenarios to demonstrate their approach to incorporating new data into patient care.

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

Hope Rugo, MD, FASCO and Aditya Bardia MD, MPH, FASCOexplore strategies for managing antibody drug conjugate (ADC)-related toxicities in breast cancer, covering current ADCs, real-world management practices, and future directions, in this OncLive Insights video series.

This educational program, led by experts Shernan Holtan, MD, and Haris Ali, MD, explores the latest strategies and emerging treatments for optimizing management of chronic graft-vs-host disease (cGVHD), including monitoring techniques, therapeutic options, and patient-reported outcomes.

A panel of experts on nasopharyngeal carcinoma review patient cases and provide comprehensive insights on treatment practices.